# A Study of Selexipag in Healthy Male Participant

> **NCT04266756** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Selexipag matrix tablet
- **DRUG:** Selexipag encapsulated pellets
- **DRUG:** Selexipag Immediate-release (IR) tablet

## Key facts

- **NCT ID:** NCT04266756
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-23
- **Primary completion:** 2020-08-14
- **Final completion:** 2020-08-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266756, "A Study of Selexipag in Healthy Male Participant". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04266756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*